Leesa Soulodre
Apart from the horrifying statistic of more than six million deaths from COVID-19 worldwide, one of the most troubling outcomes of the disease has been the surfacing of Long COVID, now affecting a subset of its survivors. A recent Lancet study reported that as many as 35 percent of those who recover from an initial bout of COVID go on to develop Long COVID. Given the voracity of this burden on worker productivity, life expectancy, and the potential avalanche on an already strained global healthcare infrastructure under the burden of aging populations and chronic disease, the race to understand better the causes and neurological effects of this lingering disease is well underway.
Individuals with Long COVID may experience a range of troubling symptoms, including difficulty concentrating, lapses in memory, and sleep disorders, all of which are also hallmarks of Alzheimer’s disease. Depression and “brain fog” are also often reported by patients with both conditions. And alarmingly, incoming research indicates that Long COVID can cause the brain to age ten to twenty years, increasing the risk of developing dementia and Alzheimer’s.
The Clue in the Cells
The pathogenesis and cognitive symptoms of Long COVID are similar to those of Alzheimer’s disease with good reason: in Long COVID, neuroinflammation can cause phosphorylated tau—one of the critical proteins that cause Alzheimer’s—to accumulate in brain cells. In addition, the symptom of hyposomia, the inability to smell and taste, is also prevalent in both diseases. These links have even led some researchers to theorize that Long COVID could be a form of Alzheimer’s, although more studies are needed to confirm this possibility.
The accuracy of ViewMind’s digital biomarker introduces the possibility of early detection and intervention for various neurocognitive disorders, including Long COVID
Further research will need to expand on these early studies’ findings to understand better the impact of Long COVID on different brain areas. The digital health and artificial intelligence company ViewMind has been using a digital biomarker to detect the presence of Alzheimer’s-related proteins, tau and beta-amyloid, in the brain long before traditional diagnostic methods. ViewMind is now embarking on a project that will employ the same digital biomarker—eye movement patterns—to better understand the pathology of Long COVID.
Partnering for Innovation
In partnership with the Luxembourg Institute of Health, ViewMind has been awarded a 1.36 million euro grant from the Luxembourg Ministry of the Economy, the Luxembourg National Research Fund, and Luxembourg’s National Innovation Agency, Luxinnovation, to study the neurocognitive effects of Long COVID. The grant was one of four awarded to projects submitted to Luxembourg’s first Joint Call for HealthTech Projects.
The joint call aims to create public-private partnerships that will provide resources for health technology companies to validate their products through technical and clinical trials before launching them to the market. ViewMind recently concluded a longitudinal study that studied the ability of its proprietary eye-tracking AI software to determine whether patients with mild cognitive impairment (MCI) would later develop Alzheimer’s. After discovering that this highly sensitive technology accurately predicted conversion to Alzheimer’s in 94 percent of participants, ViewMind now has the opportunity to test the efficacy of its technology in detecting Long COVID.
The Eyes Have It
In ViewMind’s three-year study, which monitored individuals with MCI alongside a control group, participants performed short tasks on a computer that required them to remember patterns of color in shapes they had been asked to view. Monitoring eye movement patterns and pupil response during this activity confirmed a clear biomarker for Alzheimer’s that led to near-perfect predictive accuracy.
Current methods of diagnosing Alzheimer’s typically detect the disease years or even decades after it has begun to develop. The reasons for this are threefold: patients often do not seek diagnosis until symptoms are grave; Alzheimer’s symptoms are often hard to distinguish from the signs of normal aging, and health care currently does not include routine preventive cognitive health scans that might detect neurocognitive diseases in their early stages. ViewMind’s technology holds the promise to change all that.
The accuracy of ViewMind’s digital biomarker introduces the possibility of early detection and intervention for various neurocognitive disorders, including Long COVID. The easier it is to trace the breadcrumbs of a disease’s symptoms to a definitive biomarker, the more likely researchers will be able to secure funding to study it further and forge a path to treatment and prevention.
A New Frontier
COVID-19, and the consequent Long COVID, are entirely new conditions that the research community is still working to define and treat. The path to value-based care has been prioritized in the wake of the pandemic. This pandemic has also unified national demands for more equitable access to healthcare, sustainable access to vaccines, vaccine tracking activities, real-world safety surveillance, and digital medicine.
ViewMind’s mission to create an easily accessible, affordable, and noninvasive assessment for various cognitive disorders holds great promise for identifying and treating longstanding or recently emergent conditions in their early stages. Although early intervention and treatment solutions for Alzheimer’s disease are as yet underdeveloped, the condition has been front of mind in the global consciousness for decades, a frequent subject of medical research.
To empower not only the silver economy but anyone who has had exposure to COVID-19 to live healthier, happier, and longer at home, early interventions like those offered by Viewmind may need to be at its heart.
